Functional Genetics’ core discovery technology, Random Homozygous Gene Perturbation (RHGP), provides a superior means to identify novel targets and pathways. RHGP can efficiently interrogate every gene in a cell, both for gain or loss of target function, and efficiently focus upon those targets that directly cause the desired experimental outcome.
FGI has recently improved the reliability and throughput of RHGP such that it can identify and validate targets within days or weeks, rather than months or years that is required for conventional discovery technologies.
Functional Genetics and our partners have successfully used RHGP to identify novel targets with applications to cancer (targets that cause chemotherapy resistance or metastasis), infectious disease (targets for broad-spectrum antivirals and antibiotics), Alzheimer’s disease (targets that cause amyloid plaques), manufacturing of biologics (pathways that increase the efficiency of monoclonal antibody production), and other indications.
Improvements in our technologies allow us to rapidly fill or refill our pipeline. The Company is also working with partners to allow others to fully realize the potential of the RHGP technology for target discovery.